Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Celgene Corp Sees FY 2013 Revenue Guidance To Be Right At Or Slightly Ahead Of Prior Range-Conference Call


Friday, 17 May 2013 04:00pm EDT 

Celgene Corp announced that for fiscal 2013, it expects revenue to be right at or slightly ahead of $6 billion. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.151 billion for fiscal 2013. 

Company Quote

93.34
-1.44 -1.52%
2:04pm EDT